Display options
Share it on

Ment Health Clin. 2018 Mar 26;8(2):78-85. doi: 10.9740/mhc.2018.03.078. eCollection 2018 Mar.

Review of pharmacotherapy for smoking cessation in patients with schizophrenia.

The mental health clinician

Avery E Shawen, Shannon J Drayton

Affiliations

  1. Student, Medical University of South Carolina College of Pharmacy, Charleston, South Carolina, [email protected].
  2. Associate Professor, Medical University of South Carolina College of Pharmacy, Charleston, South Carolina.

PMID: 29955550 PMCID: PMC6007740 DOI: 10.9740/mhc.2018.03.078

Abstract

Smoking cessation is a chronic issue surrounding individuals with schizophrenia. It is estimated that up to 90% of patients diagnosed with schizophrenia smoke cigarettes. The purpose of this article is to provide a nonsystematic review of the efficacy of smoking cessation interventions as well as to explore the potential neuropsychiatric adverse effects of these agents in patients with schizophrenia. Eighteen studies were found and included in the review. Overall, nicotine replacement therapy, bupropion, and varenicline have all proven their effectiveness at either promoting smoking abstinence or a significant reduction in cigarette use.

Keywords: bupropion; nicotine replacement therapy; schizophrenia; smoking cessation; varenicline

Conflict of interest statement

Disclosures: The contributors have no disclosures of interest.

References

  1. Front Neurosci. 2015 Sep 03;9:297 - PubMed
  2. Ann Clin Psychiatry. 2012 Nov;24(4):285-91 - PubMed
  3. PLoS One. 2016 Jan 05;11(1):e0143490 - PubMed
  4. Schizophr Res. 2011 Jun;129(1):94-5 - PubMed
  5. J Clin Psychiatry. 2012 May;73(5):654-60 - PubMed
  6. Schizophr Res. 2011 Mar;126(1-3):277-83 - PubMed
  7. BMJ. 2004 Feb 28;328(7438):509-11 - PubMed
  8. Lancet. 2016 Jun 18;387(10037):2507-20 - PubMed
  9. Psychopharmacology (Berl). 2011 Sep;217(2):279-87 - PubMed
  10. Drug Alcohol Depend. 2009 Sep 1;104(1-2):94-9 - PubMed
  11. JAMA Psychiatry. 2015 Dec;72(12):1172-81 - PubMed
  12. Int J Environ Res Public Health. 2013 Jan 28;10(2):446-61 - PubMed
  13. Int J Nurs Stud. 2004 Mar;41(3):321-30 - PubMed
  14. Nicotine Tob Res. 2001 Nov;3(4):397-403 - PubMed
  15. J Clin Psychopharmacol. 2013 Apr;33(2):243-7 - PubMed
  16. Schizophr Res. 2013 May;146(1-3):376-8 - PubMed
  17. J Clin Psychopharmacol. 2007 Aug;27(4):380-6 - PubMed
  18. Neuropsychiatr Dis Treat. 2005 Dec;1(4):349-55 - PubMed
  19. Psychiatr Serv. 1999 Oct;50(10):1346-50 - PubMed
  20. Neuropsychopharmacology. 1996 Nov;15(5):429-36 - PubMed
  21. Biol Psychiatry. 2008 Jun 1;63(11):1092-6 - PubMed
  22. Biol Psychiatry. 2002 Jul 1;52(1):53-61 - PubMed
  23. J Clin Psychiatry. 2004 Mar;65(3):307-11; quiz 452-3 - PubMed
  24. J Clin Psychopharmacol. 2005 Jun;25(3):218-25 - PubMed
  25. Eur Arch Psychiatry Clin Neurosci. 2013 Feb;263(1):75-82 - PubMed
  26. J Consult Clin Psychol. 2006 Dec;74(6):1153-61 - PubMed
  27. J Clin Psychiatry. 2012 Jan;73(1):95-102 - PubMed
  28. Am J Health Syst Pharm. 2007 Jul 1;64(13):1381-4 - PubMed
  29. Schizophr Res. 2004 Oct 1;70(2-3):263-75 - PubMed
  30. Schizophr Res. 2005 Jul 15;76(2-3):353-6 - PubMed
  31. Am J Psychiatry. 2000 Nov;157(11):1835-42 - PubMed
  32. JAMA. 2014 Jan 8;311(2):145-54 - PubMed

Publication Types